Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,059 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

NCT03060447
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ART
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 20, 2026, 1:00 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743
View directory record Official record
Conditions
Sjögren's Disease
Interventions
DDY391, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids

NCT01027143
View directory record Official record
Conditions
Asthma, Obesity
Interventions
omega-3 polyunsaturated fatty acids, Omega-3 Fatty Acid
Dietary Supplement · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 25 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT05185089
View directory record Official record
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 20, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

NCT01569438
View directory record Official record
Conditions
Bladder Pain Syndrome
Interventions
Gefapixant, Placebo
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
41
States / cities
Glendale, Alabama • Homewood, Alabama • Mobile, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

NCT05116826
View directory record Official record
Conditions
Moderate Hepatic Impairment, Severe Hepatic Impairment, Liver Diseases
Interventions
Nitazoxanide
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 20, 2026, 1:00 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515
View directory record Official record
Conditions
Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions
AZ-3102, Placebo
Drug
Lead sponsor
Azafaros B.V.
Industry
Eligibility
4 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 1:00 AM EDT
Active, not recruiting Not applicable Interventional

Walking Exercise Sustainability Through Telehealth for Veterans With Lower-limb Amputation

NCT05412550
View directory record Official record
Conditions
Lower-Limb Amputation
Interventions
Exercise self-management, Attention control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Not applicable Interventional Results available

Self-guided Treatment for Adolescents Navigating Depression

NCT05462652
View directory record Official record
Conditions
Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
Interventions
Active Intervention
Device
Lead sponsor
Limbix Health, Inc.
Industry
Eligibility
13 Years to 21 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

NCT01802918
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Not applicable Interventional Results available

RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers

NCT02781090
View directory record Official record
Conditions
Tobacco Use Disorder, HIV
Interventions
PSFW+, AHA, Nicotine polacrilex
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 20, 2026, 1:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

NCT01838018
View directory record Official record
Conditions
Pantothenate Kinase-associated Neurodegeneration (PKAN)
Interventions
Not listed
Lead sponsor
Susan J. Hayflick
Other
Eligibility
7 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia

NCT03056690
View directory record Official record
Conditions
Fibromyalgia
Interventions
ASP0819, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • El Cajon, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 20, 2026, 1:00 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733
View directory record Official record
Conditions
HIV-1-Infection
Interventions
Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 2 Interventional

Randomized Trial of an HIV Navigation Program for Early Palliative Care

NCT01884389
View directory record Official record
Conditions
HIV, Chronic Disease
Interventions
Patient Navigation
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

NCT06979518
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK3862995B, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

NCT03359785
View directory record Official record
Conditions
Schizophrenia
Interventions
Luvadaxistat, Matching Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 20, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

NCT01752985
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
BMS-813160, Placebo matching with BMS-813160
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 20, 2026, 1:00 AM EDT
Enrolling by invitation Not applicable Interventional

Prophylactic TBR on Phantom Limb Pain

NCT06956508
View directory record Official record
Conditions
Phantom Limb Pain After Amputation
Interventions
Targeted Brain Rehabilitation
Other
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

NCT01616524
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)

NCT05268185
View directory record Official record
Conditions
COVID-19, Vaccine Reaction, COVID-19 Pandemic
Interventions
Moderna Booster Vaccine, Pfizer Booster Vaccine
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 20, 2026, 1:00 AM EDT
Completed Not applicable Interventional

Exoskeleton-assisted Walking in SCI Inpatient Rehabilitation

NCT04013997
View directory record Official record
Conditions
Spinal Cord Injuries, Inpatients
Interventions
EksoGT
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 20, 2026, 1:00 AM EDT